Samuel Grigg
Melbourne, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a FLT3 N676K variant.
Journal: Leukemia & lymphoma
Published: July 07, 2026
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.
Journal: Nature reviews. Clinical oncology
Published: June 10, 2026
MPL W515R hereditary thrombocytosis associated with a benign long-term clinical course.
Journal: Pathology
Published: November 11, 2025
Myeloid/lymphoid neoplasms with eosinophilia and ZMYM2::FLT3 fusion: clinical, pathological and molecular clues to a cryptic diagnosis.
Journal: Pathology
Published: September 03, 2025
Genomic mechanisms associated with resistance to PDL1-blockade in a patient with mantle cell lymphoma.
Journal: Leukemia & lymphoma
Published: December 22, 2024
Rates of discordant CD20 status by flow cytometry and immunohistochemistry in B-ALL.
Journal: British journal of haematology
Published: August 26, 2024
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
Journal: British journal of haematology
Published: February 05, 2024
Nurse-initiated pre-prescribed antibiotic orders to facilitate prompt and appropriate antibiotic administration in febrile neutropenia.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: September 23, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026